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1. Introduction
Cancers originating from the colon or rectum are 
called colorectal cancer. Colorectal cancer is the third 
most common cancer type in the world and the fourth 
most common cause of cancer-related deaths [1]. Early 
diagnosis is associated with improving prognosis and 
associated with the identification of genetic biomarkers 
and the development of available diagnostic tools [2]. The 
application of gene expression profiling on carcinogenesis 
studies purposes to identify specific alterations on gene 
expression according to tumour development and to 
diagnose and classify tumours on the basis of molecular 
features [3]. Several studies have been conducted to 
investigate the difference in gene expression levels 
between tumor and normal colorectal tissues and have 
reported significant differences in gene expression profiles 
between adenoma and normal mucosa. Among these 
studies, certain groups of genes have been reported to be 
of differently expressed and consequently help distinguish 
cancerous tissues from normal ones [4–10]. Ortiz-Zapater 
et al. [11] reported that CPEB4-associated mRNAs are 
significantly enriched in a number of cellular functions that 
are relevant to tumorigenesis. The adenomatous polyposis 
coli (APC) gene is a key tumor suppressor gene. Mutations 
in APC gene are the basis of hereditary predisposition to 
colorectal cancer in familial adenomatous polyposis coli 
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(FAP) and also the primary reason for the formation of 
sporadic colorectal tumors. Mutant APC may also impair 
cytoskeleton adhesion and stability, which play a role 
in cancer progression. A better understanding of both 
genetics and biological function of APC may help develop 
preventive or therapeutic regimes that aim to reduce 
the burden of colorectal cancer over time [12]. Somatic 
mutations in the CTNNB1 gene have been identified 
in several types of cancer including include colorectal, 
liver, thyroid, ovarian, endometrial and skin cancers and 
medulloblastoma. TRIP13 has been found to play a key 
role in meiotic recombination, spindle checkpoint and 
chromosome synapses [13]. Studies have shown that 
TRIP13 is overexpressed in multiple neoplasms [14–16]. 
Sheng et al. [17] suggested that TRIP13 can support 
colorectal cancer cell proliferation, migration and invasion 
in vitro, and reported low survival times for colorectal 
cancer patients. IFNg is a critical proinflammatory 
cytokine for natural and adaptive immunity against viral 
and intracellular bacterial infections and tumor control. 
IFNg is also important for the activation of macrophages in 
response to intracellular bacteria and viruses. Decreased 
IFNg induction or signal has also been demonstrated to 
be associated with increased sensitivity to intracellular 
bacteria, some viruses and tumor onset [18]. PIK3CA is a 
proto-oncogene encoding phosphatidylinositol-3-kinases 
(PI3K) located in the EGFR tyrosine-kinase domain and 
leads to the activation of AKT’s phosphorylation and the 
AKT-mTOR signal path. The phosphoinositol-3-kinase 
(PI3K) pathway has been discovered as an enzymatic 
activity associated with a viral oncoprotein in human 
cancers. This pathway has attracted a lot of attention 
in human cancer studies because it is important for cell 
cycle, proliferation, growth, survival, protein synthesis, 
and glucose metabolism [19]. The EIF2S3 gene encodes 
the core subunit of eukaryotic translation initiation 
factor-2 (eIF2), a heterotrimeric GTP binding protein 
involved in the incorporation of methionyl-tRNA (i) into 
the 40S ribosomal subunit. EIF2 complex is required for 
protein synthesis [20]. EIF4A is a member of the DEAD 
box protein family and functions as an ATP-bound RNA 
helicase to catalyze the dissolution of the mRNA secondary 
structure at 5’UTR [21]. 
Among all the genes reported in the literature with 
their potential cause in tumor development, CPEB4, APC, 
TRIP13, EIF2S3, EIF4A1, IFNg, PIK3CA and CTNNB1 
have particularly been identified to be a set of potential 
candidates for tumor development. Therefore, in this study, 
they have been experimentally studied by considering 
their expression level in 45 colorectal cancer patients who 
were at different stages of their disease. It is discovered 
that these genes exist in tumors and peripheral bloods, but 
with varying expression levels, which appears to suggest 
that they may help distinguish patients and their disease 
stages, consequently understand molecular mechanism of 
the disease.
2. Materials and methods
2.1. Sample collection and clinicopathological 
information
Fifty patients who underwent surgical resection in the 
Department of General Surgery, Afyonkarahisar Health 
Sciences University between April 2018 and December 
2019 were chosen for the study. Tissues and blood samples 
were obtained from the patients with histopathologically 
confirmed colorectal carcinoma (26 male and 19 female 
patients). Of the fifty patients, five are noncolorectal 
cancer subjects and selected as controls. The stage of cancer 
was estimated on the basis of the TNM and American Joint 
Committee on Cancer classifications.  
2.2. RNA extraction, real-time PCR and RT-PCR analyses
The fresh samples were transported in liquid nitrogen and 
stored in –80 °C until RNA extraction. About 5 mL pe-
ripheral blood samples were stored in EDTA-coated vacu-
tainers and RNA extractions were immediately performed. 
RNA extractions of tissues and peripheral blood samples 
were performed by using EZ-RNA Total RNA extraction 
kit (BI, Israel, Cat. No: 20-400-100) according to the man-
ufacturer’s protocol. Then, RNA amount and RNA purity 
were quantified for each RNA sample by Nanodrop ND-
1000 spectrophotometer V3.7. RNA samples were stored 
at –80 °C until use. All the RNA samples were reverse 
transcribed into cDNA from 1 µg of total RNA (iScript 
Reverse Transcription Supermix, Bio-Rad Laboratories, 
Hercules, CA, USA, Cat. No: 170884) under the follow-
ing conditions: One cycle at 25 °C for 5 min, 46 °C for 20 
min and 95 °C for 1 min. Real-time PCR was performed 
after reverse transcription. mRNA expression analysis of 
all the genes  was performed by using the Rotor Gene-Q 
(Qiagen, Hilden, Germany).  cDNAs that belong to the 
cases were added to iTaq Universal SYBR Green Supermix 
(Biorad Laboratories, Kat. No: 1725122) according to the 
manufacturer’s protocol. Oligonucleotide primers were 
designed by Oligomere Biotechnology (Ankara, Turkey) 





















We used the following RT-PCR protocol for CPEB4, APC, 
TRIP13, EIF2S3, EIF4A1, CTNNB1: 95 °C for 30 s initial 
denaturation followed by 40 cycles of 95 °C for 5 s and 60 
°C for 30 s, and for IFNg, PIK3CA: 95 °C for 30 s initial 
denaturation followed by 40 cycles of 95 °C for 5 s and 
63 °C for 30 s. Melting curve analysis was performed for 
confirmation of single product amplification at the end of 
the PCR. 65–95 °C, 0.5 °C increments at 5 s/step. Each run 
has been performed triplicate.
2.3. Statistical analysis
All the data analyses were performed using REST 2009 
V2.0.13 and SPSS v.19 software which use pairwise fixed 
reallocation randomization test [22] where P < 0.05 is 
deemed to represent a statistically significant result. 
REST 2009 Software is a standalone tool for analysis of 
gene expression data from quantitative, real-time PCR 
experiments. The analysis or quantitation of relative gene 
expression uses expression of reference genes to normalize 
expression levels of genes of interest in different samples.
3. Results 
The study included 45 patients (average age: 66.6 ± 12.66) 
with pathologically proven colorectal carcinoma and 5 
control patients (average age: 62.5 ± 11.08). Cancer tissues 
and blood samples were collected for each of the cases. In 
colorectal cancer, tumor localization was in the rectum for 
17 patients and in the colon for 26 patients. Of 45 patients, 
the number of patients at stages I, II, III and IV are 8, 17, 
15 and 5, respectively. 
3.1. Gene expression analysis
The mRNA levels of CPEB4, APC, TRIP13, EIF2S3, 
EIF4A1, IFNg, PIK3CA and CTNNB1 genes expressed in 
colorectal cancer tissue specimens, colorectal cancer blood 
samples, normal colon tissues and blood samples were 
analysed. 
3.1.1. mRNA analysis of CPEB4, APC, TRIP13, EIF2S3, 
EIF4A1, IFNg, PIK3CA and CTNNB1 genes expressed in 
normal and cancer tissues
Changes in mRNA levels of related genes expressed in 
tumor tissues of colorectal cancer (CRC) cases were 
determined according to the tissues of the control 
group. While the mRNA levels of CPEB4 and APC genes 
decreased significantly compared to the control group 
(0.512 and 0.594 fold regulation value, respectively) (P < 
0.05), the mRNA level of the TRIP13 gene significantly 
increased (2.139) (P < 0.05). The mRNA levels of EIF2S3 
and IFNg genes increased compared to the control group, 
while the mRNA level of EIF4A1, PIK3CA and CTNNB1 
genes decreased (Figure 1).
3.1.2 mRNA analysis of CPEB4, APC, TRIP13, EIF2S3, 
EIF4A1, IFNg, PIK3CA and CTNNB1 genes expressed in 
normal and cancer peripheral blood samples
Changes in mRNA levels of related genes expressed in 
peripheral blood samples of colorectal cancer cases were 
determined according to the peripheral blood samples of 
the control group. The mRNA levels of the CPEB4, APC, 
EIF2S3 and EIF4A1 genes were significantly increased 
Figure 1. The results of real-time PCR analysis. The up/down regulation of genes in tissues of colorectal cancer (CRC) patient were 
given as fold regulation levels. * represents the significance of P< 0.05 compared to control. GAPDH is reference gene for normalization.
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compared to the control group (2.467; 2.066; 1.852; 1.522 
fold regulation value; respectively) (P < 0.05). The mRNA 
levels of TRIP13, IFNg, PIK3CA and CTNNB1 genes also 
increased (Figure 2).
3.1.3. mRNA analysis of CPEB4, APC, TRIP13, EIF2S3, 
EIF4A1, IFNg, PIK3CA and CTNNB1 genes expressed in 
tumor tissues of stages I–IV colorectal cancer patients
Changes in mRNA levels of related genes expressed in 
tumor tissues of stages I–IV colorectal cancer cases were 
determined according to the tissues of the control group. 
The findings for each stage are as follows:
Stage I: The mRNA levels of the CPEB4 and CTNNB1 
genes decreased significantly compared to the control 
group [0.250 (P < 0.001); 0.204 (P < 0.05) fold regulation 
value; respectively]. While TRIP13 and EIF2S3 mRNA 
levels increased compared to the control group, mRNA 
levels of APC, EIF4A1, IFNg  and PIK3CA genes decreased 
(Figure 3). 
Stage II: While mRNA levels of CPEB4, APC, PIK3CA and 
CTNNB1 genes decreased compared to the control group, 
TRIP13, EIF2S3, EIF4A1 and IFNg mRNA levels increased 
(Figure 4). 
Stage III:  mRNA levels of CPEB4, APC, EIF4A1, PIK3CA 
and CTNNB1 genes decreased compared to the control 
group, whereas TRIP13, EIF2S3 and IFNg mRNA levels 
increased (Figure 5). 
Stage IV:  The mRNA level of the APC gene significantly 
decreased compared to the control group [0.333 fold 
regulation value, (P < 0.05)]. In addition, CPEB4, EIF2S3, 
EIF4A1 PIK3CA and CTNNB1 mRNA levels decreased 
compared to the control group, while TRIP13 and IFNg 
mRNA levels increased (Figure 6).
3.1.4. mRNA analysis of CPEB4, APC, TRIP13, EIF2S3, 
EIF4A1, IFNg, PIK3CA and CTNNB1 genes expressed 
in peripheral blood samples of stages I–IV colorectal 
cancer patients
Changes in mRNA levels of related genes expressed in 
peripheral blood samples of stages I–IV colorectal cancer 
cases were determined according to the peripheral blood 
samples of the control group. The findings for each stage 
are as follows: 
Stage I:  The mRNA levels of CPEB4, TRIP13, EIF2S3, 
CTNNB1, EIF4A1 genes significantly increased compared 
to the control group [2.803; 3.553; 2.507; 3.548 (P < 0.05); 
2.441; (P < 0.001) fold regulation value; respectively]. The 
mRNA levels of the APC, IFNg and PIK3CA genes also 
increased compared to the control group (Figure 7). 
Stage II: The mRNA levels of CPEB4 and TRIP13 genes 
significantly increased compared to the control group 
[2.788; 1.943 fold regulation value (P < 0.05)]. The mRNA 
levels of the APC, EIF2S3, EIF4A1 and CTNNB1 genes also 
increased compared to the control group, while the mRNA 
levels of the IFNg and PIK3CA genes decreased (Figure 8). 
Stage III: The mRNA levels of APC, TRIP13, EIF2S3 and 
EIF4A1 genes significantly increased compared to the 
control group [2.47; 2.696; 2.32; 1.838 fold regulation 
value (P < 0.05)]. The mRNA levels of CPEB4, IFNg, 
PIK3CA and CTNNB1 genes also increased compared to 
the control group (Figure 9). 
Stage IV: While mRNA levels of CPEB4, APC and 
PIK3CA genes increased compared to the control group, 
TRIP13, EIF2S3, EIF4A1, IFNg and CTNNB1 mRNA levels 
decreased (Figure 10).
Figure 2. The results of real-time PCR analysis. The up regulation of genes in peripheral blood of colorectal cancer patient were given as 
fold regulation levels. * represents the significance of P < 0.05 compared to control. GAPDH is reference gene for normalization. 
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4. Discussion
In colorectal cancer, a comprehensive list of biomarkers with 
quite different expression patterns can be used as molecular 
markers to complement existing histopathological factors 
in patients’ follow-up and treatment strategies. Although 
screening tests are becoming increasingly important, colon 
cancer cases are often diagnosed at an advanced stage of the 
tumor, where the chances of survival are greatly reduced. It 
is well known that various gene expression differences can 
be detected during colon cancer development. On the basis 
of all genome expression studies, it is intended to identify 
clinically useful biomarkers and then be developed and 
used as part of routine diagnosis in tumor classification 
[23]. 
4.1. Relationship between colorectal cancer and CPEB4 
gene expression
Abnormal expression of CPEB4 is associated with certain 
types of cancer, suggesting that CPEB4 can play critical 
roles in the control of cancer proliferation and metastasis 
[24]. In particular, it is suggested that CPEB4 plays an 
important role in the migration and invasion of cancer 
Figure 3. The results of real-time PCR analysis. The up/down regulation of genes in tissues 
of stage I colorectal cancer patients were given as fold regulation levels. * represents the 
significance of P < 0.05 compared to control. GAPDH is reference gene for normalization. 
Figure 4. The results of real-time PCR analysis. The up/down regulation of genes 
in tissues of stage II colorectal cancer patients were given as fold regulation levels. 
GAPDH is reference gene for normalization. 
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cells in certain types of cancer, and can be used as a target 
for cancer treatment [11, 24–26]. In addition, it is of 
great interest to identify cancer-associated RNA-binding 
proteins, to understand colorectal cancer biology, and 
to potentially set new goals with cancer treatment and 
prognostic biomarkers [27]. It has been reported that 
colorectal cancer tissues express high levels of CPEB4 and 
that high mRNA level is associated with advanced tumor 
stage, lymph node metastasis, distant metastasis and poor 
prognosis in patients with colorectal cancer [28]. 
In our study, CPEB4 mRNA level was significantly 
decreased in all colorectal tumor tissues. However, similar 
to our study, Xu and Liu [24] reported that CPEB4’s mRNA 
level decreased compared to control in prostate cancer 
and adjacent tissues. Considering the studies, there are 
different results related to CPEB4 in different types of 
tumor tissues. CPEB4 is thought to affect tumor growth, 
invasion and vascularization by applying preoncogenic 
effects, since the high level of expression of CPEB4 has 
been defined in a wide variety of malignancies [11]. In 
addition, CPEB4 gene expression has been reported to be 
relatively low in NSCLC samples compared to adjacent 
non-cancerous tissues [29]. In another study, CPEB4 gene 
expression was reported to increase in pancreatic ductal 
Figure 5. The results of real-time PCR analysis. The up/down regulation of genes in tissues of 
stage III colorectal cancer patients were given as fold regulation levels. GAPDH is reference gene 
for normalization. 
Figure 6. The results of real-time PCR analysis. The up/down regulation of genes in tissues 
of stage IV colorectal cancer patients were given as fold regulation levels. * represents the 
significance of P < 0.05 compared to control. GAPDH is reference gene for normalization. 
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carcinoma [11] but decreased in hepatocellular carcinoma 
[30]. When liver samples taken from 125 hepatocellular 
carcinoma patients were compared with 49 controls, it 
was reported that the protein level of CPEB4 increased 
in early stage hepatocellular carcinoma and decreased in 
late stage hepatocellular carcinoma [31]. These changes 
in the expression of CPEB4 during the progression of 
hepatocellular carcinoma suggest that it plays a complex 
role in tumorigenesis. It has been suggested that CPEB4 
gene expression is directly proportional to the pathological 
degree of glioma, increased CPEB4 gene expression in 
primary tumors in predicting poor outcomes in patients, 
and suppressed CPEB4 gene expression inhibits tumor 
cell proliferation and is a potential therapeutic target for 
glioblastoma [32]. However, Hu et al. [33] reported that 
CPEB4 gene expression increases significantly in glioma 
and this increase is directly proportional to the advanced 
cancer stage. It has been reported that for patients with 
glioma, CPEB4 may be a highly sensitive prognostic 
indicator. It is thought that CPEB4 is over-expressed in a 
wide variety of tumors, including colorectal cancer, skin 
cancer and kidney cancer, and high expression of CPEB4 
Figure 7. The results of real-time PCR analysis. The up regulation of genes in peripheral blood of 
stage I colorectal cancer patients were given as fold regulation levels. * represents the significance of 
P<0.05, ** represents the significance of P< 0.001 compared to control. GAPDH is reference gene for 
normalization. 
Figure 8. The results of real-time PCR analysis. The up/down regulation of genes in 
peripheral blood of stage II colorectal cancer patients were given as fold regulation levels. 
* represents the significance of P < 0.05. GAPDH is reference gene for normalization. 
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may also be effective in tumor development. It has been 
suggested that CPEB4 is important in tumor invasion 
and metastasis processes, and high expression level is an 
indicator for poor outcome in colorectal cancer patients 
[34]. In addition, Xu and Liu [24] reported a similar 
result in invasive and metastatic cancers. In addition, 
CPEB4 has also been reported to be highly expressed 
in the peripheral blood of cases with colorectal cancer 
[35]. Similar to this study, in our study, CPEB4 mRNA 
level increased significantly in the peripheral blood of 
patients with colorectal cancer. When compared in terms 
of stages, this increase was important in stages I and II. 
This suggests that CPEB4 gene expression in peripheral 
blood from the early stages of colorectal cancer may be an 
indicator for colorectal cancer. It has been suggested that 
such gene expression changes may be related to different 
pathways regulated by CPEB4 in different types of cells. It 
has been suggested that such gene expression changes may 
be related to different pathways regulated by CPEB4 in 
different types of cells [29]. In our study, while the mRNA 
level of the CPEB4 gene was significantly decreased in all 
colorectal tumor tissues of the cases, it was observed that 
it is increased significantly in peripheral blood samples. 
When evaluated comparatively in terms of stages, the 
increase in the mRNA level of CPEB4 gene was found to 
be statistically significant in the peripheral blood samples 
of cases in colorectal cancer stages I and II. This suggests 
that the increase in CPEB4 mRNA level in peripheral 
Figure 9. The results of real-time PCR analysis. The up regulation of genes in peripheral blood of 
stage III colorectal cancer patients were given as fold regulation levels. * represents the significance 
of P < 0.05 compared to control. GAPDH is reference gene for normalization. 
Figure 10. The results of real-time PCR analysis. The up/down regulation of genes in peripheral 
blood of stage IV colorectal cancer patients were given as fold regulation levels. GAPDH is reference 
gene for normalization.
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blood since the early stages of colorectal cancer may be a 
potential biomarker for colorectal cancer. 
4.2. Relationship between colorectal cancer and APC 
gene expression
Although there are many studies related to APC mutations 
in literature searches, there is not much study on gene 
expression. Birnbaum et al. [36] investigated the role of 
the APC gene in the 183 colon adenocarcinoma series, by 
combined analysis of gene expression, mutation, allelic 
loss, and promoter methylation and metastasis formation. 
While spot mutations were detected in 73% of cases and 
allelic losses in 39% of cases; 59% of tumors showed 
bialelic inactivation. No relationship was found between 
the number and type of APC gene expression changes 
and metastatic transformation. The results show that 
determining the APC status cannot help for the prediction 
of metastasis and cannot be used to classify stage II colon 
cancers. In our study, the mRNA level of the APC gene 
was significantly decreased in all colorectal tumor tissues, 
while the peripheral blood of the same cases increased 
significantly. When compared in stages, this increase was 
also important in stage III. When evaluated in terms of 
stages, while the increase in the mRNA level of the APC 
gene in the peripheral blood samples of the patients 
in colorectal cancer stage III, the decrease in stage IV 
tumor tissues was significant. These results indicate that 
determining APC mRNA levels cannot assist in predicting 
colorectal cancer and cannot be used to classify the stages 
of colon cancer.
In the study of Güler [37], 8 of 20 patients with 
colorectal carcinoma reported that there was a mutation 
in the APC gene, whereas in the rest, the expression 
of the APC gene was significantly different compared 
to the control group. It has been suggested that APC is 
overexpressed in NIH3T3 fibroblast cells to block cell 
cycle progression from serum-induced G0/G1 to S phase 
[38]. Consistent with these data, it has been suggested 
that APC is overexpressed to prevent transition to the 
G1 phase in colorectal cancer cell lines. This function is 
partially associated with the regulation of the β-catenin/
Tcf mediated transcription of S-phase regulators such as 
cyclic D1 and c-myc [39]. It has been suggested that APC 
can also affect proliferation independently of β-catenin. 
Thus, deactivation of the mutant APC at the G1/S control 
point can contribute to aberrant cell proliferation. Copy 
number changes, regulatory changes, deletions, severe 
mutations and other potential causes are difficult to 
distinguish through APC mRNA expression data. In other 
words, more studies are needed to demonstrate causality 
correlation with respect to APC mRNA changes. The 
results obtained as a result of mRNA analyses are not 
sufficient for any necessary information such as mutation 
status and other clinicopathological features. Further 
study is therefore required for developing preventive or 
therapeutic strategies that may be developed over time, 
especially aimed at reducing the colorectal cancer burden.
4.3. Relationship between colorectal cancer and CTNNB1 
gene expression
The CTNNB1 gene encodes β-catenin. β-catenin plays an 
important role in the adhesion of cells and communication 
between cells. Somatic mutations in the CTNNB1 gene 
have been identified in many types of cancer. If β-catenin 
does not phosphorylate and therefore does not break down, 
it accumulates in the cellular cytoplasm and nucleus. The 
accumulation of the β-catenin may result from the Wnt 
signal [40] by inactivation of the APC or direct mutation of 
the β-catenin itself [41]. Mutations in the APC or CTNNB1 
genes inhibit GSK3β-mediated phosphorylation followed 
by β-catenin degradation [42] and result in activation of 
the catenin transcription [43]. This critical role of Wnt 
in intestinal homeostasis is the basis for understanding 
why Wnt path deregulation contributes to colorectal 
carcinogenesis. Of the known Wnt signal cascades, Wnt/
β-catenin (canonical pathway) mutates in about 90% of 
colorectal cancers. These mutations are mainly found in 
the genes of APC and β-catenin and both lead to pathway 
activation, but other path components may also harbor 
mutations [44]. Signal activation of Wnt-β-catenin leads to 
accumulation of catenin, which can be detected in >80% of 
colorectal cancer tumors in the nucleus [45]. In addition, 
high nuclear catenin levels have been correlated with poor 
prognosis in colorectal cancer patients [46]. In our study, 
CTNNB1 mRNA level decreased in tumor tissues compared 
to the control group, while it increased in peripheral blood 
samples. In particular, different mRNA levels were found 
in stage I colorectal cancer tissues and peripheral blood 
samples. These different results we obtained support the 
view that the changes in CTNNB1 mRNA level may not be 
useful in colorectal cancer diagnosis.
4.4. Relationship between colorectal cancer and TRIP13 
gene expression
TRIP13 has been found to play a key role in meiotic 
recombination, spindle checkpoint and chromosome 
synapses [13]. Studies have shown that TRIP13 is 
overexpressed in multiple neoplasms [14–16]. TRIP13 has 
been shown to be a localized protein in the kinetochore 
that allows cell division to progress correctly. A number 
of kinetochore-localized proteins are highly synthesized 
in various cancers, and their expression is associated with 
genomic imbalance or malignant transformation of cancer 
cells [47]. Although it plays an important role in meiotic 
regulation, excessive expression or amplification of TRIP13 
has been found in more than one human cancer [48,49]. 
In our study, TRIP13 mRNA level increased significantly 
in both colorectal tumor tissues and peripheral blood 
compared to the control group. Similarly, Kurita et al. 
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[50] analyzed the mRNA level of TRIP13 between normal 
and tumor tissues. They suggest that TRIP13 is involved 
in colorectal cancer cell proliferation and invasion, 
and may be a potential indicator for colorectal cancer 
treatment. Sheng et al. [17] analyzed multiple colorectal 
cancer datasets available from Oncomine to determine 
the expression profile of TRC13 in colorectal cancer, and 
found that gene expression of TRIP13 increased in tumor 
tissue compared to that of normal tissue. To confirm the 
results, 41 pairs of colorectal cancers and TCGA (Cancer 
Genome Atlas) examined the mRNA level of TRIP13 in the 
corresponding normal tissues, and reported that TRIP13 
was expressed in tumor tissue at a high rate (P < 0.001).
In our study, the increase in TRIP13 mRNA level is 
important especially in peripheral blood stages I, II, and 
III. In the development of colorectal cancer, high mRNA 
level of TRIP13 can be observed from the early stage. 
Sheng et al. [17] reported that high TRIP13 expression 
was significantly associated with advanced pTNM stage. 
High TRIP13 expression has been shown to reveal poor 
course in other carcinomas such as renal renal clear cell 
carcinoma, renal papillary cell carcinoma, brain low grade 
glioma, liver hepatocellular carcinoma in total survival 
(OS: overall survival) analysis. Therefore, abnormal 
expression of TRIP13 is a common occurrence in cancer 
cells. It shows a potential oncogenic role of TRIP13 
in cancer development [51]. Considering the findings 
mentioned above, TRIP13 appears to contribute to tumor 
formation and tumor progression in various human 
cancers. In human mycosis fungoides tumor, TRIP13 gene 
expression increased compared to control biopsies [52]. 
What is important here is that TRIP13 gene expression 
and activity are required for accurate chromosome 
segregation. It is strongly suggested that TRIP13 is an 
oncogene when it is possible to monitor the suitability of 
chromosome segregation with various pathways and its 
effects on cell physiology [50]. Our results support this view. 
In our study, TRIP13 mRNA levels increased significantly 
in both colorectal tumor tissues and peripheral blood 
samples compared to controls. This increase in peripheral 
blood samples, especially in cases of colorectal cancer 
stages I, II, and III, seems to be significant. An increase 
in the level of mRNA of TRIP13 can be observed in the 
development of colorectal cancer from an early stage. 
TRIP13 strongly suggests that overexpression may be a 
common phenotype in colorectal cancer and a potential 
finding/biomarker for early stage colorectal cancer 
diagnosis.
4.5. Relationship between colorectal cancer and IFNg 
gene expression
Interferons can also have a bidirectional effect on cancer 
cell behavior, such as promoting proliferation or growth 
inhibition. Indeed, contradictory results have been report-
ed regarding the interferons function as tumor promoters 
or tumor suppressors in melanoma and colorectal cancer. 
The differences may arise from different experimental en-
vironments, such as the effect of the microenvironment, 
the amount and quality of the immune infiltrate, and the 
mutation status of cancer cells. Therefore, there is a need 
to better understand the biology of interferons in cancer 
and analyze the data depending on the conditions [53]. In 
our study, IFNg mRNA levels increased in tumor tissues 
and peripheral blood samples of colorectal cancer group 
compared to the control group. However, this increase was 
not statistically significant. When the data were evaluated 
in terms of stages, different changes were observed in the 
mRNA levels according to the data of the control group 
individuals. Studies to clarify the effect of IFNg on the 
colorectal cancer process are very new and future studies 
are needed.
4.6. Relationship between colorectal cancer and PIK3CA 
gene expression
PIK3CA is a proto-oncogene encoding 
phosphatidylinositol-3-kinases (PI3K) located in the 
EGFR tyrosine-kinase domain. It leads to phosphorylation 
of AKT (protein kinase B) and activation of the AKT-
mTOR signaling pathway. The phosphoinositol-3-kinase 
(PI3K) pathway has been discovered as an enzymatic 
activity associated with a viral oncoprotein in human 
cancers. This pathway has attracted a lot of attention 
in human cancer studies because it is important for cell 
cycle, proliferation, growth, survival, protein synthesis 
and glucose metabolism [19]. In our study, it was found 
that PIK3CA mRNA levels decreased in colorectal 
tumor tissues compared to control, while it increased in 
peripheral blood compared to the control group. However, 
these changes are not statistically significant. PIK3CA, the 
catalytic subunit of PI3K, undergoes mutation in many 
different tumors, including colorectal cancer [54,55]. 
PIK3CA mutations have been reported in about 80% of 
mutations in 10%–20% of colorectal cancers, exon 9 and 
exon 20 at two hot spots [55]. It has been suggested that 
PIK3CA mutations may be a long-sought biomarker for 
successful adjuvant therapy with aspirin in colorectal 
cancer patients. Therefore, PIK3CA mutations appear to 
be a promising biomarker; however, they reported that 
more studies are needed to precisely define the effect of 
somatic mutations in the PIK3CA gene in the treatment of 
colorectal cancer patients [56].
Yan et al. [57] investigated the potential value and 
mechanism of PIK3CA mutation in colorectal cancer 
chemotherapy. First line chemotherapy response and 
PIK3CA mutation correlation were evaluated and 
evaluated in 440 colorectal cancer patients in medical 
records. The frequency of PIK3CA gene mutation in 
colorectal cancer patients has been found to be 9.55%, 
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and this has been reported to be associated with late TNM 
staging and low histological grade. Colorectal cancer 
patients with the PIK3CA mutation have been reported 
to respond poorly to primary chemotherapy than those 
without the PIK3CA mutation. PIK3CA mutation tumor 
cells showed poor sensitivity to first-line chemotherapy 
in vitro and in vivo. The findings showed that PI3K/Akt 
activation induced by the PIK3CA mutation contributes 
to the survival and proliferation of colorectal cancer stem 
cells, in which cells are more resistant to chemotherapy. 
In colorectal cancer studies, conflicting results have 
been reported about the use of PIK3CA, which may be a 
predictive marker for treatment. Recent metaanalyses have 
shown that mutations in PIK3CA exon 20 may be a marker 
for resistance to anti-EGFR treatment [58,59].
When the outcomes of the studies are evaluated, 
mutation analyses come to the fore rather than PIK3CA 
mRNA expression analysis. However, the relationship 
between PIK3CA mutations and the prognosis of colorectal 
cancer patients remains unclear. 
In our study, PIK3CA mRNA levels decreased in 
colorectal tumor tissues compared to control, while 
in peripheral blood samples increased compared to 
the control group. However, these changes were not 
statistically significant. When the outcomes of the studies 
are evaluated, in PIK3CA; mutational analysis is more 
prominent than mRNA analysis. However, the relationship 
between PIK3CA mutations and the prognosis of colorectal 
cancer patients remains controversial. In early diagnosis of 
patients with colorectal cancer, mRNA analyses associated 
with mutation analyses are needed to precisely identify the 
PIK3CA effect.
4.7. Relationship between colorectal cancer and EIF2S3 
gene expression
EIF2 complex is required for protein synthesis [20]. In our 
study, EIF2S3 mRNA levels increased in both colorectal 
tumor tissues and peripheral blood samples compared 
to the control group. This increase is only important for 
the change in the level of EIF2S3 mRNA expressed in the 
peripheral blood of the cases. This increase is especially 
important in stages I and III peripheral blood samples. 
There are not many studies in the literature for EIF2S3 
mRNA analysis. According to the data obtained in our 
study, the increase in EIF2S3 mRNA level in peripheral 
blood samples stands out in colorectal cancer cases and 
our data contributes to these limited studies. Further study 
is therefore required to understand EIF2S3 mRNA changes 
in peripheral blood samples of colorectal cancer patients. 
4.8. Relationship between colorectal cancer and EIF4A1 
gene expression
To the best of our knowledge, there are no more studies 
in the literature regarding EIF4A1 mRNA gene expression 
changes. In our study, EIF4A1 mRNA level in colorectal 
tumor tissues decreased compared to the control group, 
while it increased in peripheral blood compared to the 
control group. This increase is important both in the 
expression in general peripheral blood and especially 
in peripheral blood stages I and III. The malignant 
phenotype is the result of largely irregular gene expression. 
Transformed cells are due to not only a global increase in 
protein synthesis, but also a situation where pro-oncogenic 
mRNAs increase translationally. Such mRNAs have been 
shown to have longer and more structured 5p-UTRs 
that require high levels of eukaryotic initiation factor 
4A (EIF4A1) helicase activity for effective transcription. 
Therefore, EIF4A1 has begun to attract attention for 
cancer therapy. In order to be used as a biomarker in 
early diagnosis, detailed studies should be developed on 
the mechanisms that make specific mRNAs dependent on 
EIF4A1 activity [60]. According to the results presented 
in this study, the increase in EIF4A1 mRNA level in 
peripheral blood samples stands out in colorectal cancer 
cases and our results further  contributes to these limited 
studies. Further study is therefore required to understand 
EIF4A1 mRNA changes in peripheral blood samples of 
colorectal cancer patients. 
5. Conclusion
The results reported in this study appears to suggest that the 
increase in TRIP13 and CPEB4 mRNA levels in peripheral 
blood samples of colorectal cancer cases may be a potential 
biomarker in early stage diagnosis of colorectal cancer. 
Considering the results related to EIF2S3 and EIF4A1 
mRNA changes in the patients with colorectal cancer, 
the increase in mRNA levels in peripheral blood samples 
is remarkable. The major differences in mRNA levels in 
peripheral blood samples and tumor tissue samples likely 
reflect the tissue-specific specific regulatory mechanisms 
for related gene. Increases in the level of mRNA observed 
in the early stage of colorectal cancer suggest that relevant 
genes may play a role in carcinogenesis. Our data contains 
genetic information that may contribute to existing 
procedures in terms of diagnosis and prognosis in patients 
with colorectal cancer.
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